Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: N-acetylcysteine
Drug: Placebo

First Posted Date: 2011-11-10

Last Posted Date: 2018-08-28

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 50

Registration Number: NCT01470027

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Prevention of Serious Adverse Events Following Angiography

Phase 3

Completed

Conditions: Kidney Disease
Acute Renal Failure
Coronary Artery Disease

Interventions: Drug: IV isotonic saline
Drug: IV isotonic bicarbonate
Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2011-11-08

Last Posted Date: 2022-10-03

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 5177

Registration Number: NCT01467466

Locations: 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸
Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States

and more 51 locations

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

Phase 1

Completed

Conditions: Gaucher's Disease
Parkinson's Disease

Interventions: Drug: N-acetylcysteine

First Posted Date: 2011-09-01

Last Posted Date: 2019-11-01

Lead Sponsor: University of Minnesota

Target Recruit Count: 9

Registration Number: NCT01427517

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

A Clinical Trial for CTD-ILD Treatment

Phase 2

Terminated

Conditions: Interstitial Lung Disease
Connective Tissue Disease

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2011-08-26

Last Posted Date: 2017-04-06

Lead Sponsor: University of Michigan

Target Recruit Count: 5

Registration Number: NCT01424033

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes

Not Applicable

Completed

Conditions: Oxidative Stress
Type 2 Diabetes

Interventions: Drug: N-acetylcysteine

First Posted Date: 2011-07-14

Last Posted Date: 2016-06-17

Lead Sponsor: Utzschneider, Kristina, M.D.

Target Recruit Count: 13

Registration Number: NCT01394510

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft

Phase 4

Completed

Conditions: Postoperative Acute Kidney Injury After Off-pump Coronary Artery Bypass Graft

Interventions: Drug: N-acetylcysteine
Drug: Saline

First Posted Date: 2011-07-14

Last Posted Date: 2013-03-06

Lead Sponsor: Yonsei University

Target Recruit Count: 115

Registration Number: NCT01394419

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

Phase 1

Completed

Conditions: Aging

Interventions: Drug: Placebo losartan
Drug: N-acetylcysteine
Drug: Losartan
Drug: Placebo N-acetylcysteine

First Posted Date: 2011-06-29

Last Posted Date: 2018-05-08

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 6

Registration Number: NCT01384591

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

N-acetylcysteine to Prevent Renal Failure

Not Applicable

Conditions: Kidney Failure, Acute
Oxidative Stress Induction

Interventions: Drug: Control
Drug: N-acetylcysteine

First Posted Date: 2011-05-25

Last Posted Date: 2011-05-25

Lead Sponsor: Instituto do Coracao

Target Recruit Count: 50

Registration Number: NCT01359722

Locations: 🇧🇷
Instituto do Coracao, Sao Paulo, Brazil

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

Phase 2

Completed

Conditions: Schizophrenic Psychoses

Interventions: Drug: Placebo
Drug: n-acetylcysteine

First Posted Date: 2011-05-16

Last Posted Date: 2017-07-05

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT01354132

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts Mental Health Center, Boston, Massachusetts, United States

Protective Effect of N-acetylcysteine Against From Ototoxicity

Phase 2

Completed

Conditions: Hearing Loss, Extreme

Interventions: Drug: N-acetylcysteine

First Posted Date: 2011-01-06

Last Posted Date: 2011-11-16

Lead Sponsor: TC Erciyes University

Target Recruit Count: 60

Registration Number: NCT01271088

Locations: 🇹🇷
Erciyes University, Kayseri, Turkey

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy